Assessment of reasonable

To determine whether it is reasonable to grant permission for a clinical trial to proceed, FDA evaluates potential risk based on results derived from analytical assessment of product characteristics as well as preclinical proof-of-concept and safety testing, which,  collectively, are considered within the context of a proposed clinical study